Technology behind blockbuster Covid jabs is yielding promising results in oncology treatment
Patrick Temple-West in New York
The revolutionary mRNA technology that made Moderna a corporate superstar during the Covid-19 pandemic has turbocharged the vaccine maker again, this time thanks to the promise it holds in treating cancer.
The biotechnology group’s share price closed 177 per cent higher on Wednesday after it reported successful trial results for an experimental cancer therapy.
